Auvin Stéphane
Department of Pediatric Neurology, Lille University Hospital, Pharmacology Laboratory, Lille School of Medicine, Lille, France.
CNS Neurosci Ther. 2008 Fall;14(3):227-33. doi: 10.1111/j.1527-3458.2008.00046.x.
Drug treatment of juvenile myoclonic epilepsy (JME) is mainly based on clinical experience and prospective and retrospective studies, with little evidence from randomized clinical trials. There are almost no head-to-head comparisons between old and new antiepileptic drugs (AEDs). Valproate is the drug of the first choice in men with JME. In women, lamotrigine (LTG) should be preferred regarding teratogenicity and side effects of valproate. Levetiracetam (LEV) is also effective. Recent data suggest that it may soon be used as first line treatment. Some AEDs can aggravate JME. In addition to AEDs, nonpharmacological treatments are important in JME. JME usually requires lifelong treatment because seizures nearly always return after withdrawal of therapy.
青少年肌阵挛癫痫(JME)的药物治疗主要基于临床经验以及前瞻性和回顾性研究,来自随机临床试验的证据很少。新旧抗癫痫药物(AEDs)之间几乎没有直接对比。丙戊酸盐是男性JME的首选药物。对于女性,考虑到丙戊酸盐的致畸性和副作用,应优先选择拉莫三嗪(LTG)。左乙拉西坦(LEV)也有效。最近的数据表明,它可能很快会被用作一线治疗。一些抗癫痫药物会加重JME。除了抗癫痫药物,非药物治疗在JME中也很重要。JME通常需要终身治疗,因为停药后癫痫发作几乎总会复发。